Menu
Menu
Adapted from Dr. Weei-Yuarn Huang’s (Sunnybrook Health Centre, Ontario, Canada) presentation during the webinar “Evaluating Next-Generation Sequencing Solutions for Real-World Clinical Needs in Myeloid Malignancy,” with permission from the author - This concordance study demonstrates the strong analytical performance of the new SOPHiA DDM™ Community Myeloid Solution and its potential to streamline and consolidate myeloid genomic analysis within a single workflow.
About Dr. Weei-Yuarn Huang
Weei-Yuarn Huang is currently the medical director of molecular diagnostics at Sunnybrook Health Science Center in Toronto, Ontario. Under his leadership, the laboratory has become one of largest tumor NGS testing centers in Ontario. He has published more than 50 peer-reviewed manuscripts and served as a member in advisory boards for molecular testing both provincially and nationally.
SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise.
SOPHiA DDM™ Dx Hereditary Cancer Solution, SOPHiA DDM™ Dx RNAtarget Oncology Solution and SOPHiA DDM™ Dx Homologous Recombination Deficiency Solution are available as CE-IVD products for In Vitro Diagnostic Use in the European Economic Area (EEA), the United Kingdom and Switzerland. SOPHiA DDM™ Dx Myeloid Solution and SOPHiA DDM™ Dx Solid Tumor Solution are available as CE-IVD products for In Vitro Diagnostic Use in the EEA, the United Kingdom, Switzerland, and Israel. Information about products that may or may not be available in different countries and if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact us to obtain the appropriate product information for your country of residence.
All third-party trademarks listed by SOPHiA GENETICS remain the property of their respective owners. Unless specifically identified as such, SOPHiA GENETICS’ use of third-party trademarks does not indicate any relationship, sponsorship, or endorsement between SOPHiA GENETICS and the owners of these trademarks. Any references by SOPHiA GENETICS to third-party trademarks is to identify the corresponding third-party goods and/or services and shall be considered nominative fair use under the trademark law.
